Open Access

Zoledronic acid suppresses transforming growth factor-β-induced fibrogenesis by human gingival fibroblasts

  • Authors:
    • Yuko Komatsu
    • Miho Ibi
    • Naoyuki Chosa
    • Seiko Kyakumoto
    • Masaharu Kamo
    • Toshiyuki Shibata
    • Yoshiki Sugiyama
    • Akira Ishisaki
  • View Affiliations

  • Published online on: May 10, 2016     https://doi.org/10.3892/ijmm.2016.2582
  • Pages: 139-147
  • Copyright: © Komatsu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Bisphosphonates (BPs) are analogues of pyrophosphate that are known to prevent bone resorption by inhibiting osteoclast activity. Nitrogen-containing BPs, such as zoledronic acid (ZA), are widely used in the treatment of osteoporosis and bone metastasis. However, despite having benefits, ZA has been reported to induce BP-related osteonecrosis of the jaw (BRONJ) in cancer patients. The molecular pathological mechanisms responsible for the development of BRONJ, including necrotic bone exposure after tooth extraction, remain to be elucidated. In this study, we examined the effects of ZA on the transforming growth factor-β (TGF‑β)-induced myofibroblast (MF) differentiation of human gingival fibroblasts (hGFs) and the migratory activity of hGFs, which are important for wound closure by fibrous tissue formation. The ZA maximum concentration in serum (Cmax) was found to be approximately 1.47 µM, which clinically, is found after the intravenous administration of 4 mg ZA, and ZA at this dose is considered appropriate for the treatment of cancer bone metastasis or bone diseases, such as Erdheim-Chester disease. At Cmax, ZA significantly suppressed i) the TGF‑β-induced promotion of cell viability, ii) the TGF‑β-induced expression of MF markers such as α-smooth muscle actin (α-SMA) and type I collagen, iii) the TGF‑β-induced migratory activity of hGFs and iv) the expression level of TGF‑β type I receptor on the surfaces of hGFs, as well as the TGF‑β-induced phosphorylation of Smad2/3. Thus, ZA suppresses TGF‑β-induced fibrous tissue formation by hGFs, possibly through the inhibition of Smad‑dependent signal transduction. Our findings partly elucidate the molecular mechanisms underlying BRONJ and may prove to be beneficial to the identification of drug targets for the treatment of this symptom at the molecular level.
View Figures
View References

Related Articles

Journal Cover

July 2016
Volume 38 Issue 1

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Komatsu, Y., Ibi, M., Chosa, N., Kyakumoto, S., Kamo, M., Shibata, T. ... Ishisaki, A. (2016). Zoledronic acid suppresses transforming growth factor-β-induced fibrogenesis by human gingival fibroblasts. International Journal of Molecular Medicine, 38, 139-147. https://doi.org/10.3892/ijmm.2016.2582
MLA
Komatsu, Y., Ibi, M., Chosa, N., Kyakumoto, S., Kamo, M., Shibata, T., Sugiyama, Y., Ishisaki, A."Zoledronic acid suppresses transforming growth factor-β-induced fibrogenesis by human gingival fibroblasts". International Journal of Molecular Medicine 38.1 (2016): 139-147.
Chicago
Komatsu, Y., Ibi, M., Chosa, N., Kyakumoto, S., Kamo, M., Shibata, T., Sugiyama, Y., Ishisaki, A."Zoledronic acid suppresses transforming growth factor-β-induced fibrogenesis by human gingival fibroblasts". International Journal of Molecular Medicine 38, no. 1 (2016): 139-147. https://doi.org/10.3892/ijmm.2016.2582